Financial Results for quarter and half year ended September 30, 2025
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Shree Ganesh Remedies Limited submitted its unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2025. Standalone revenue from operations for Q2 FY26 stood at ₹3,031.50 lakhs compared to ₹3,233.19 lakhs in Q2 FY25, while H1 FY26 revenue was ₹5,498.29 lakhs vs ₹5,711.18 lakhs in H1 FY25. Profit after tax for Q2 FY26 was ₹495.57 lakhs (vs ₹641.57 lakhs YoY) and H1 FY26 PAT was ₹840.51 lakhs (vs ₹1,106.76 lakhs YoY), showing a YoY decline. EPS for H1 FY26 was ₹6.55. The board also accepted the resignation of Mr. Priyam Surendra Shah as Independent Director, effective November 7, 2025, citing pre-occupation, with the director confirming no other material reasons. The auditors (Chaudhary Shah & Associates) issued an unqualified review report.
The results show a YoY decline in both revenue and profitability, with H1 PAT dropping roughly 24%, which may weigh on investor sentiment. The independent director's exit is routine and not a governance red flag, but the company must fill the vacancy to maintain board composition requirements.